Product and Pipeline

More effective combination treatments for cancer

Cancers are complex dynamic and adaptive diseases with the tumor micro-environment comprising many different cell types, matrix proteins and secreted molecules.

The interplay between these elements impacts the responsiveness to therapy and whether there is continued tumor survival and progression, even in the face of continued treatments. We believe that remodelling of the tumor microenvironment and taking a multi-pathway and multi-target approach offers an opportunity to significantly improve response rates and durability of response.

Oncology Pipeline

Description

Product – Indications Preclinical Phase 1 Phase 2 Phase 3 Status
SP-002 Platform
SP-002: Phase 2/3
Basal Cell Carcinoma (BCC) – H/M-Zone

Phase 2/3		 Phase 2 studies completed.
Commence Phase 2/3 in 2027
SP-002: Phase 1/2
Cutaneous SCC

Phase 1/2
Open IND
Phase 1/2 ready
Vector-Drug Conjugate Platform
SP-537
Pancreatic Cancer / H&N SCC

Preclinical
IND-enabling work ongoing
SP-563
Non-Muscle Invasive Bladder Cancer

Preclinical
IND-enabling work ongoing
SP-588
Organ Confined Prostate Cancer / DCIS-T1 Breast Cancer

Preclinical
IND-enabling work ongoing
Completed
Planned Activity
Future

SP-002

SP-002 is an adenoviral vector (serotype 5, Ad5) encoding the therapeutic cytokine Interferon-γ. The vector has been engineered to be replication-deficient so it can transduce cells and produce Interferon-γ, but not new viral particles (a safety feature not present in oncolytic viruses).

Recombinant Interferon-γ protein has shown superior potency in tumors when compared with Interferon-α, however, its successful clinical application in cancer has been hampered by its narrow therapeutic window. The main advance of SP-002 is a wider therapeutic window as transduced tumors release a therapeutically-effective dose of IFN-γ locally, without causing significant systemic toxicities.

Novel Viral Vector + Drug Conjugate Platform

SP-5001: Deliver the drug + Engineer susceptibility

Designed to overcome major pathways of cancer resistance

  • Complementary attack: Produces interferon-γ and delivers drugs that work synergistically with it to efficiently activate/restore programmed cell death pathways
  • Wider treatment window: Improves the balance between effective dosing and toxicity
  • Flexible targeting: Combines genetic and drug payloads, with engineered linkers that provide selectivity where linkers are cleaved
  • High drug-carrying capacity: Accommodates substantial drug payloads on each vector

Utilizing clinically proven SP-002 with clinically validated small-molecule payloads to accelerate first-in-human studies

1 First-generation viral–drug conjugates will use clinically validated SP-002 as the vector backbone for conjugation to clinically validated small-molecule drugs

Novel Viral Vector + Drug Conjugate Platform